Gilenya; Norw. : Gilenya; Spain: Gilenya; Swed.: Gilenya; reintroduction of fingolimod if treatment has been stopped Oxerutins (BAN) for more than 2 weeks, and the precautions for re�initiating Switz.: Gilenya; Turk.: Gilenya; UK: Gilenya; USA: Gilenya. treatment outlined above should be followed. Hidroxileti!rut6sidos; Hydroxyethyir�tosides; Oxerutlnas: Fingolimod may increase the risk of developing 0Kcepynmot infections due to the reduction in peripheral lymphocyte Flavonoid Compounds Description. Oxerutins consist of a mixture of 5 different count (see Uses and Administration, p. 2504.3), and 0-(P-hydroxyethyl)rutosides, not less than 45% of which is mo f!avonoides; 8iofiavonoids; Flavonoides: Vitarnin treatment should not be started in patients without a recent P troxerutin (trihydroxyethylrutoside, below), but which also Substances; Vitamlnas full blood count taken within the previous 6 months. P; Quercetin for 2 months after treatment has stopped. Stopping Benzqueccina; Benzquercine; Benzquercinum; 6et!3KB€PLi�H. fingolimod should be considered if a patient develops a 3,3',4';5,7-Pentakis(benzyloxy) flavone. Quercetina; Keep:.;erv.H: 3,3',4',5,7-Pentahydroxyftavone. serious infection during treatment, and then the risks versus C,oKNJ0,=752.9 2-(3,4-Dihydroxyphenyl)-3,5,7-trihy droxy�4H- 1 -benzopyran- benefits reassessed before treatment is resumed. 4--one, Patients without a history of chickenpox or who have not C4$ - 13157-90-9. received varicella Mzoster vaccination should be tested for UN/! - 499L710 905. C:sH",0,=302.2 antibodies to varicella-zoster virus. Vaccination should be 015 - 117-39·5. - considered in antibody-negative patients before starting Diosmin (BAN, r/NN) dihydraUN/I te). 91KMOi5T!£ (quercetin); 53803V78AI5 {quercetin fingolimod treatment. which should then be delayed for one Barosmin; Buchu Resin; Diosmetin -Rutinoside; Diosmiini; month after vaccination. Giving any live attenuated vaccine 7 should be avoided during, and for 2 months after stopping, Dlosmln�; Diosmtnas; Dios.mlr:e; Diosminum; Oiozmlr.; Rutoside (BAN, r!NN! fingolimod treatment because of the risk of infection. ,[jHOCMl1H. Rutin; Rutina; Rutosid; Rutosid:Trihydrat; IMoside trihydrat�; Macular oedema has been reported in some patients Trihydroxy:4'-meth oxyflavone [6-0·(6-deoxy-;:H 3'.5 .7- 7- Rutosidi; Rutosiditrih�dro.iitti; Rut6sido; Rutosic!trihyc! rat; taking fingolimod, and ophthalmologic evaluation should mannopyranosylj-p,c;-glucopyraf!oside]. Rutosidurn; Rutosidurn Trihydricum: Rutozidas trihidratas; be carried out before starting treatment and routinely about Rutozid�Flavonoids are naturally occurring phenolic compounds Caution should also be exercised when switching patients to Leucociariidoium; Leucocyanidin; Leucocyanldo!; JleC! that are widely distributed in plants, occurring in the free fingolimod from long-acting drugs such as natalizumab and KOL\I1aHH;:tOn. state and also as glycosides. The main types of flavonoids are mitoxantrone. 2-(3i4cDihydroxyphenyi)chroman-3.4,5,7:tetrof. anthocyanins, chalcones, flavonols, flavones, and flavo Ketoconazole increases the blood concentrations of Ccsii�<0,=306.3 nones. Flavonoids act as antoxidants and claims have been fingolimod and fingolimod phosphate, and so patients C4S made for many medicinal uses. Preparations containing taking the two drugs together should be closely monitored. natural or semisynthetic flavonoids are thought to improve Patients taking beta blockers, or class la or class (!Nfi - capillary function by reducing abnormal leakage. They have antiarrhythmics should be closely monitored when givenill been given to relieve capillary impairment and venous fingolimod because of the risk of decreased heart rate (see Monoxerutin (r/NN) insufficiency of the lower lhnbs, and for haemorrhoids. Adverse Effects and Precautions, p. 2504.3). Monohidroxietiirut6sidos; Monohydroxyethylrutosides; It has been suggested that flavonoids present in some For use of vaccines with fingolimod, see Adverse Effects foods, such as fruit, vegetables, tea, and red wine may MMok!ierutiini; Monoxerutina: Monoxerutine; Monoxeruti and Precautions, p. 2504.3. protect against the development of atherosclerosis nirm: r'vlOHOKCepyTMK. (p. 1250.2). 7-(13-Hydroxyethyl)ruroside. C::r9�?<40;)��54.6 References. 1. Knekt P, et al. Flavonoid intake and coronary mortality in Finland: (details are given in Volume B) ProprietaryPreparations C4S -· 23869-24- 1. cohort study. BMJ 1996; 312: 478-8 1. 2. Hertog MGL, et al. Antioxidant flavonols and coronary heart disease risk. Austral.: Gilenya; Canad.: Gile Single-ingredient Preparations. ATt -'- C050102. Lancet 1997; 349: 699. nya; Denm.: Gilenya; Fr.: Gilenya; Ger.: Gilenya; Gr.: Gilenya; ATC Ve t - QC05CA02. 3. Youdim KA et a!. Dietary f\avonoids as potential neuroprotectants. Bioi Irl. : Gilenya; Israel: Gilenya; Jpn: Gilenya; Imusera; Neth.: UN/I ...:._ EKF7043SBU. Chem 2002; 383: 503-19. The symbol denotes a preparation no longer actively marketed t